COMPARISON OF BLEEDING EVENTS BETWEEN FACTOR XA INHIBITORS AND VITAMIN K ANTAGONISTS IN PATIENTS WITH ATRIAL FIBRILLATION PATIENTS AT "X" HOSPITAL, MALANG CITY
DOI:
https://doi.org/10.5614/api.v51i1.26347Keywords:
Atrial Fibrillation, Bleeding, Factor Xa Inhibitor, Vitamin K AntagonistAbstract
Cardiovascular disease is the leading cause of death worldwide and poses a major public health challenge. Arrhythmia is a common health issue encountered in hospitals, with atrial fibrillation (AF) being the most prevalent type. AF is characterized by irregular atrial activation, which can impair heart function. The anticoagulant to Vitamin K Antagonists (VKA) has long been used as a therapeutic strategy for AF, but it has limitations, particularly regarding bleeding risk. Factor Xa inhibitors, like Rivaroxaban or Apixaban may serve as alternative therapies for AF due to their safety profiles and lower risk of bleeding. This study aims to analyze the incidence of bleeding events in the use of factor Xa inhibitors compared with VKA in AF patients, based on clinical manifestations and/or laboratory data such as aPTT/PT and INR values, at ?X? Hospital Malang City during the 2019?2024 period. This research is an analytical observational study with a retrospective cross-sectional design based on medical record data. The results revealed that there was a significant difference in bleeding events between factor Xa inhibitors and VKA groups based on clinical manifestations and/or laboratory data (p-value 0.006). Patients using VKA had a higher proportion of bleeding events (46.7%) compared to those using factor Xa inhibitors (15.2%). AF patients treated with VKA experienced a higher incidence of bleeding events compared to those treated with factor Xa inhibitors.
References
Abdolmanafi A, Duong L, Dahdah N, Adib IR, Cheriet F, 2018, Characterization of Coronary Artery Pathological Formations from OCT Imaging Using Deep Learning, Biomedical Optics Express 9 (10): 4936?4960, doi: 10.1364/BOE.9.004936.
Al?Aref SJ, Maliakal G, Singh G, Rosendael AR, Ma X, Xu Z, Alawamlh OAH, Lee B, Pandey M, Achenbach S, Al-Mallah MH, Andreini D, Bax JJ, Berman DS, Budoff MJ, Cademartiri F, Callister TQ, Chang HJ, Chinnaiyan K, Chow BJW, Cury RC, DeLago A, Feuchtner G, Hadamitzky M, Hausleiter J, Kaufmann PA, Kim YJ, Leipsic JA, Maffei E, Marques H, Gonlves PA, Pontone G, Raff GL, Rubinshtein R, Villines TC, Gransar H, Lu Y, Jones EC, Pe JM, Lin FY, Min JK, Shaw LJ, 2020, Machine Learning of Clinical Variables and Coronary Artery Calcium Scoring for The Prediction of Obstructive Coronary Artery Disease on Coronary Computed Tomography Angiography: Analysis from The CONFIRM Registry, European Heart Journal 41(3): 359-367, doi:10.1093/eurheartj/ehz565.
Alberts M, Chen YW, Lin JH, Kogan E, Twyman K, Milentijevic D, 2020, Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin, Stroke 51(2): 549?555, doi: 10.1161/STROKEAHA.119.025554.
Allen A, Barnes GD, 2023, Direct Oral Anticoagulants Versus Vitamin K Antagonist in Elderly Patients With Atrial Fibrillation: Sometimes Less Is More, but Sometimes More Is More, Journal of the American Heart Association 12 (21): 1-3, doi: 10.1161/JAHA.123.032127.
Alshehri AM, 2019, Stroke in Atrial Fibrillation: Review of Risk Stratification and Preventive Therapy, Journal of Family and Community Medicine 26 (2): 92?97, doi: 10.4103/jfcm.JFCM_99_18.
Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Bahit C, Benz AP, Bohula EA, Chao TF, Dyal L, Ezekowitz M, Fox KAA, Gencer B, Halperin JL, Hijazi Z, Hohnloser SH, Hua K, Hylek E, Kato ET, Kuder J, Lopes DR, Mahaffey KW, Oldgren J, Piccini JP, Ruff CT, Steffel J, Wojdyla D, Granger CB, 2022, Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex, Circulation 145(4): 242?255, doi: 0.1161/CIRCULATIONAHA.121.056355.
Heijman J, Luermans JGLM, Linz D, van Gelder IC, Crijns HJGM, 2021, Risk Factors for Atrial Fibrillation Progression, Cardiac Electrophysiology Clinics 13 (1): 201?209, doi: 10.1016/j.ccep.2020.10.011.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom- Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, Meir ML, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, van Gelder ICV, van Putte BP, Watkins CL, 2021, 2020 ESC Guidelines for The Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with The European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC, European Heart Journal 42 (5): 373?498, doi: 10.1093/eurheartj/ehaa612.
Hu P, Huang J, Lu Y, Zheng M, Li H, Duan X, Deng H, Zhao W, Liu X, 2022, Circulating Sex Hormones and Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis, Cardiovascular Medicine 9: 952430, doi: 10.3389/fcvm.2022.952430.
Huang YL, Chen CY, Chu CC, 2022, Risk of Major Bleeding and Thromboembolism in Asian Patients with Nonvalvular Atrial Fibrillation Using Direct Oral Anticoagulants Versus Warfarin. International Journal of Clinical Pharmacy 44 (1): 34?43, doi: 10.1007/s11096-021-01309-z.
IRAMA RSSA, 2019, Proposal Kovablik 2019, Inovasi dan Layanan Aritmia Paripurna. https://rsusaifulanwar.jatimprov.go.id/inovasi-rujukan-dan-layanan-aritmia-paripurna/. (Accessed on 5 April 2025)
Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, van Wagoner DR, 2024, 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Journal of the American College of Cardiology 149 (1), 1-156, doi: 10.1161/CIR.0000000000001193.
Kornej J, Bschel CS, Benjamin EJ, Schnabel RB, 2020, Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights, Circulation Research 127 (1): 4?20, doi: 10.1161/CIRCRESAHA.120.316340.
Kovacs RJ, Flaker GC, Saxonhouse SJ, Doherty JU, Birtcher KK, Cuker A, Davidson BL, Giugliano RP, Granger CB, Jaffer AK, Mehta BH, Nutescu E, Williams KA, 2015, Practical Management of Anticoagulation in Patients With Atrial Fibrillation, Journal of the American College of Cardiology 65 (13): 1340?1360, doi: 10.1016/j.jacc.2015.01.049.
Li H, Song X, Liang Y, Bai X, Huo WSL, Tang C, Chen W, Zhao L, 2022, Global, Regional, and National Burden of Disease Study of Atrial Fibrillation/Flutter, 1990?2019: Results from A Global Burden of Disease Study, 2019, BMC Public Health 22 (1): 1-13, doi: 10.1186/s12889-022-14403-2.
Nelson AJ, Alexander JH, 2019, Anticoagulation-Related Major Bleeding in Patients With Atrial Fibrillation: Looking Behind the Curtain, Circulation 140 (22): 1802?1804, doi: 10.1161/CIRCULATIONAHA.119.043318.
Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C, Chondrogianni M, Bovi P, Carletti M, Cappellari M, Zedde M, Ntaios G, Karagkiozi E, Athanasakis G, Makaritsis K, Silvestrelli G, Lanari A, Ciccone A, Putaala J, Tomppo L, Tatlisumak T, Rahim AHA, Lees KR, Alberti A, Venti M, Acciarresi M, D?Amore C, Becattini C, Mosconi MG, Cimini LA, Soloperto R, Masotti L, Vannucchi V, Lorenzini G, Tassi R, Guideri F, Acampa M, Martini G, Sohn SI, Marcheselli S, Mumoli N, Lodovici MLD, Bono G, Furie KL, Tadi P, Yaghi S, Toni D, Letteri F, Tassinari T, Kargiotis O, Lotti EM, Flomin Y, Mancuso M, Maccarrone M, Giannini N, Bandini F, Pezzini A, Poli L, Padovani A, Scoditti U, Denti L, Consoli D, Galati F, Sacco S, Carolei A, Tiseo C, Gourbali V, Orlandi G, Giuntini M, Chiti A, Giorli E, Gialdini G, Corea F, Ageno W, Bellesini M, Colombo G, Monaco S, Baronello MM, Karapanayiotides T, Caso V, 2017, Early Recurrence and Major Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation Treated with Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study, Journal of the American Heart Association 6 (12), doi: 10.1161/JAHA.117.007034.
Patel S, Singh R, Preuss CV, Patel N, 2024, Warfarin, StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK470313/. (Accessed on 5 April 2025)
Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), 2019, Pedoman Tata Laksana Fibrilasi Atrium Nonvalvular, Edisi 2, Jakarta.
Pinzon RT, Astyari GAPIBS, Tarigan L, 2017, Antitrombotik berdasarkan Skor CHA2DS2-VASc dan Skor HAS BLED terhadap Pola Pengobatan pada Pasien Stroke Iskemik dengan Fibrilasi Atrium, Pharmaciana 7 (1): 63, doi: 10.12928/pharmaciana.v7i1.4716.
Sawu SD, Prayitno AA, Wibowo YI, 2022, Analisis Faktor Risiko Pada Kejadian Masuk Rumah Sakit Penyakit Jantung Koroner di Rumah Sakit Husada Utama Surabaya, Jurnal Sains dan Kesehatan 4(1):10-18, doi: 10.25026/jsk.v4i1.856.
Senoo K, Proietti M, Lane DA, Lip GYH, 2016, Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin, The American Journal of Medicine 129 (6): 600?607, doi: 10.1016/j.amjmed.2015.10.001.
Suryoputri MW, Ilma DL, Endriastuti NE, 2025, Pemantauan Penggunaan Antikoagulan terhadap Perubahan Nilai aPTT pada Pasien Kardiovaskuler. Indonesian Journal of Clinical Pharmacy 14(2): 60-77, doi: 10.15416/ijcp.2025.v14i2.49454.
Tan CSS, Lee SWH, 2021, Warfarin and Food, Herbal or Dietary Supplement Interactions: A Systematic Review, British Journal of Clinical Pharmacology 87 (2): 352?374, doi: 10.1111/bcp.14404.
Ueda I, Kohsaka S, Ikemura N, Kimura T, Katsumata Y, Takemura R, Suzuki M, Takatsuki S, Koide D, Fukuda K, 2024, Patient Concern Regarding Bleeding Side Effects from Oral Anticoagulation Therapy for Atrial Fibrillation: An Analysis from The Multicentre KiCS-AF Registry, European Journal of Cardiovascular Nursing 23 (4): 358?366, doi: 10.1093/eurjcn/zvad094.
Vimalesvaran K, Dockrill SJ, Gorog DA, 2018, Role of Rivaroxaban in The Management of Atrial Fibrillation: Insights from Clinical Practice, Vascular Health and Risk Management 14: 13?21, doi: 10.2147/VHRM.S134394.
Wang YP, Kehar R, Iansavitchene A, Lazo-Langner A, 2020, Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies, TH Open 4(3):e145-e152, doi: 10.1055/s-0040-1714918.
Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA, 2016, Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation, Journal of the American Heart Association 5 (6): 1-16, doi: 10.1161/JAHA.116.003725.
Zirlik A, Bode C, 2017, Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation, Journal of Thrombosis and Thrombolysis 43(3): 365?379, doi: 10.1007/s11239-016-1446-0.
